The association between Epstein-Barr virus subtype, human leukocyte antigen class I alleles, and the development of posttransplantation lymphoproliferative disorder was examined in a group of 25 bone marrow transplant recipients. A highly statistically significant correlation was observed between the human leukocyte antigen B51 allele and development of posttransplantation lymphoproliferative disorder ( ). P p .0016 This study provides, to our knowledge, the first evidence that the human leukocyte antigen B51 allele might predispose bone marrow transplant recipients to Epstein-Barr virusassociated posttransplantation lymphoproliferative disorder.
transplant (BMT) is ∼1%. The highest incidence occurs during the first 6 months after transplantation [4] . Risk factors, such as unrelated or HLA-mismatched donors, T cell depletion, and specific prophylaxis treatment for graft rejection, clearly increase the frequency of occurrence of PTLD [3] . However, it is still not known to what extent distinct EBV strain variants or certain HLA alleles are differentially associated with EBVrelated PTLD.
In EBV subtyping, attention has been focused on variations in genes with known or presumed oncogenic functions, as well as on CTL epitope variations. One of the most intensively investigated genes in this regard is the latent membrane protein 1 (LMP1), an EBV proto-oncogene. Four LMP1 groups, termed A through D, have been classified [5] . Recently, we showed that at least 5 distinct EBV type I EBNA3 variants can be identified among European EBV isolates, in addition to the B95.8 prototype [6] . The aim of this study was to examine the potential associations between EBV subtypes, characterized by variations in their EBNA3 and LMP1 genes, the patients' HLA class I molecule types, and the development of PTLD.
Patients, materials, and methods. Patients were selected for analysis according to the following criteria: (1) receipt of allogeneic BMT between 1999 and 2002 at the Department of Hematology, Erasmus University Medical Center Rotterdam (Rotterdam, The Netherlands), and (2) EBV reactivation during the follow-up period after transplantation, with a progression to EBV DNA load levels 11000 copies/mL in plasma, as detected by a previously described PCR assay [7] . Of these patients, all individuals who developed EBV-associated PTLD within 1 year after transplantation ( ) were included in the study, and n p 14 22 patients from the non-PTLD group were randomly chosen for study inclusion. Diagnosis of EBV-associated PTLD was performed as described by van Esser et al. [8] using histological and/or cytological findings according to the criteria of Knowles et al. [9] . All patient samples carrying EBV type I strains were subjected to the typing of the EBNA3 variant, and the LMP1 group and those samples in which the EBV type I strains could be fully characterized were included in the study. A total of 25 samples met these criteria, including 13 of 14 samples from patients with PTLD and 12 of 22 samples from patients without PTLD. The median age of the study patients was 39 years (range, 19-55 years). All samples were obtained between 1999 and 2003 and were stored at Ϫ80ЊC until their use in the current study.
Viral genomic DNA was extracted from plasma samples using a QIAamp Viral RNA Mini Kit (Qiagen). EBV strains were classified as type I on the basis of the DNA sequence divergence within the N-terminal regions of EBNA3A and EBNA3C of the EBV genome [10] . Two polymorphic sites of the EBV genome-the EBNA3 locus and the LMP1 locus-were chosen as the basis for subtype assignment. PCR amplification and DNA sequence analyses were carried out in the N-terminal regions of EBNA3A and EBNA3C, in the C-terminal regions of EBNA3A and EBNA3B, and in the C-terminal region of LMP1 using B95.8 prototype-specific primers, as described elsewhere [6] . The resulting DNA sequences were grouped according to EBNA3 variant and LMP1 group (table 1) . Results and discussion. When relating the distinct EBNA3 variants to the occurrence of PTLD, statistically evident differences were observed, especially for the EBNA3 variant 1, which was detected in 66% of the BMT recipients without PTLD, but in only 23% of the patients with PTLD (P p , by Fisher's exact test) (table 1). These data suggest that .0472 the EBNA3 variant 1 might be somehow less tumorigenic than the other variants, but this suggestion, of course, requires confirmation by a larger cohort. The frequency of PTLD was also compared for the distinct LMP1 groups and for the different EBNA3 variant-LMP1 group combinations (table 1) . Although some differences were found between patients with PTLD and patients without PTLD, no statistically significant association could be identified.
HLA-restricted, EBV-specific CTLs are important for controlling latent EBV infection and for preventing PTLD development [11] . To assess a possible relationship between HLA alleles, EBV variant strains, and the development of PTLD, we evaluated the distribution of the HLA alleles A and B in this cohort. These data are also presented in table 1. All BMT recipients whose data were analyzed in the present study were fully matched (related or unrelated) with the donors, and HLA typing was based on the results of serological and sequencebased analysis. The most striking observation was that 8 (61.5%) of the 13 BMT recipients who developed PTLD expressed an HLA B51 allele, whereas the B51 allele was not present in any of the 12 patients without PTLD ( , by P p .0016 Fisher's exact test). We then investigated all patients carrying an HLA B51 allele in the BMT cohort who had received a transplant within the period 1999-2002. Overall, 19 patients were identified as carrying an HLA B51 allele; of these, 2 died immediately after undergoing transplantation. Of the remaining 17 patients, 8 (47%) developed PTLD, whereas 9 had either a low EBV load or no EBV load at all during the first year after receipt of a transplant. Given that PTLD has been described as occurring in ∼1% of patients after receipt of a BMT [3] , our data indicate a highly significant correlation between the HLA B51 allele and PTLD and a high risk of developing PTLD for BMT recipients harboring an HLA B51 allele. Although several markers located in the HLA class I region have already been found to be significantly associated with EBV-positive Hodgkin lymphoma [12] , this is, to our knowledge, the first report to show an association between the human major histocompatibility complex class I molecule HLA B51 and EBV disease leading to PTLD. The HLA B51 allele has already been shown to be of significance in other diseases. It is believed to be the disease-susceptibility gene for Behcet disease [13] and is also believed to be associated with a slow progression of AIDS [14] . Of interest, HLA B51 is a slow-assembly molecule for antigen presentation [15] and shows a generally low affinity for peptides [16] . Therefore, it seems feasible that individuals with HLA B51 may exhibit an impaired EBV-specific CTL response. In addition to a severely compromised immune system in BMT recipients, the presence of HLA B51 could facilitate the uncontrolled proliferation of EBV-infected B cells.
These data led us to further screen for B51-restricted CTL epitope sequences and for the presence of putative epitope variations in the different EBV variants. We searched for the highest-scoring B51-restricted epitopes in the immunodominant latent antigens EBNA3A, EBNA3B, and EBNA3C using 2 different HLA-binding prediction programs [17, 18] TPV of EBNA3C) were determined for the 8 patients with PTLD showing the appropriate HLA B51 background. In 3 of the patients, the EBV strains exhibited a distinct variation in the B51-restricted epitope located in the C-terminal region of EBNA3A in relation to the B95.8 prototype sequence. Instead of 914 GPETRRVVV, they exhibited the variant epitope, DHEPRRVVV, for which a reduced HLA binding was predicted, suggesting a decreased immune response to these EBV strain variants. All of the other B51-restricted epitopes analyzed in our patient samples, however, were highly conserved, which more strongly suggests that the association of the B51 allele with PTLD development is independent from EBNA3 variations. Although the statistically significant association between HLA B51 and PTLD development in the present cohort is striking, the present findings require confirmation by other investigators. In addition, some aspects need further clarification-for example, the fact that, in all of our patients with PTLD, only a single HLA B51 allele was present, as well as the fact that some of these patients possessed other HLA alleles for which dominant CD8 + T cell epitopes for EBV have been described [19] . Thus, it could also be conceivable that another genetic marker located in the HLA region is linked with the B51 allele and might contribute to PTLD development, rather than the HLA B51 allele itself.
In conclusion, our findings provide, to our knowledge, the first evidence that the major histocompatibility complex class I molecule HLA B51 is significantly correlated with the development of PTLD in BMT recipients. Further large-scale investigations and functional analyses will be needed to confirm the present findings before the HLA B51 allele can be generally accepted as a risk factor predisposing BMT recipients to PTLD.
